Figure 4. Loss of miR-203 sensitizes mice to DMBA/TPA skin carcinogenesis.
(A) Representative images of tumors that were formed in the skin of WT and miR-203 null mice treated with DMBA/TPA. (B) miR-203−/− mice have a larger tumor burden than miR-203+/+ counterparts (n = 6 and 7 miR-203+/+ and miR-203−/− animals respectively, mean ± SEM displayed, £ = p < 0.05, Whitney–Mann U-test one-sided). (C) miR-203−/− tumor size distribution is similar to wild-type animals (ns = non-significant, Student's t-test two sided, median displayed as bar). (D, E) miR-203+/+ and miR-203−/− papillomas display similar morphologies and histology. (F) Proliferation and differentiation dynamics are similar between miR-203+/+ and miR-203−/− tumors. (Scale bars = 50 μm).
Figure 4—figure supplement 1. The HrasQ61L mutation is common in both miR-203+/+ and miR-203−/− tumors.
(A) Representative end-point PCR followed by XbaI digestion. The HrasQ61L allele produces 120 bp and 87 bp product, whereas wild-type produces a 207-bp product (B) Table with quantification of genotyping results. non-significant p > 0.05, chi-squared test.